These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 24399715

  • 1. Contribution of the mGluR7 receptor to antiparkinsonian-like effects in rats: a behavioral study with the selective agonist AMN082.
    Konieczny J, Lenda T.
    Pharmacol Rep; 2013; 65(5):1194-203. PubMed ID: 24399715
    [Abstract] [Full Text] [Related]

  • 2. The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats.
    Konieczny J, Wardas J, Kuter K, Pilc A, Ossowska K.
    Neuroscience; 2007 Mar 16; 145(2):611-20. PubMed ID: 17224239
    [Abstract] [Full Text] [Related]

  • 3. The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
    Johnson KA, Jones CK, Tantawy MN, Bubser M, Marvanova M, Ansari MS, Baldwin RM, Conn PJ, Niswender CM.
    Neuropharmacology; 2013 Mar 16; 66():187-95. PubMed ID: 22546615
    [Abstract] [Full Text] [Related]

  • 4. Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata.
    Broadstock M, Austin PJ, Betts MJ, Duty S.
    Br J Pharmacol; 2012 Feb 16; 165(4b):1034-45. PubMed ID: 21627638
    [Abstract] [Full Text] [Related]

  • 5. Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease.
    Lopez S, Turle-Lorenzo N, Acher F, De Leonibus E, Mele A, Amalric M.
    J Neurosci; 2007 Jun 20; 27(25):6701-11. PubMed ID: 17581957
    [Abstract] [Full Text] [Related]

  • 6. Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.
    Greco B, Lopez S, van der Putten H, Flor PJ, Amalric M.
    J Pharmacol Exp Ther; 2010 Mar 20; 332(3):1064-71. PubMed ID: 19940105
    [Abstract] [Full Text] [Related]

  • 7. AMN082-a metabotropic glutamate receptor type 7 allosteric agonist in the NAc facilitates extinction and inhibits the reinstatement of morphine-induced conditioned place preference in male rats.
    Vatankhah M, Sarihi A, Komaki A, Shahidi S, Haghparast A.
    Brain Res Bull; 2018 Jun 20; 140():28-33. PubMed ID: 29605484
    [Abstract] [Full Text] [Related]

  • 8. Off-target potential of AMN082 on sleep EEG and related physiological variables: Evidence from mGluR7 (-/-) mice.
    Ahnaou A, Raeyemaekers L, Huysmans H, Drinkenburg WHIM.
    Behav Brain Res; 2016 Sep 15; 311():287-297. PubMed ID: 27211063
    [Abstract] [Full Text] [Related]

  • 9. The effects of metabotropic glutamate receptor 7 allosteric agonist N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride on developmental sevoflurane neurotoxicity: role of extracellular signal-regulated kinase 1 and 2 mitogen-activated protein kinase signaling pathway.
    Wang WY, Wang H, Luo Y, Jia LJ, Zhao JN, Zhang HH, Ma ZW, Xue QS, Yu BW.
    Neuroscience; 2012 Mar 15; 205():167-77. PubMed ID: 22244976
    [Abstract] [Full Text] [Related]

  • 10. The metabotropic glutamate receptor 7 (mGluR7) allosteric agonist AMN082 modulates nucleus accumbens GABA and glutamate, but not dopamine, in rats.
    Li X, Gardner EL, Xi ZX.
    Neuropharmacology; 2008 Mar 15; 54(3):542-51. PubMed ID: 18155073
    [Abstract] [Full Text] [Related]

  • 11. Group III mGluR7 and mGluR8 in the amygdala differentially modulate nocifensive and affective pain behaviors.
    Palazzo E, Fu Y, Ji G, Maione S, Neugebauer V.
    Neuropharmacology; 2008 Sep 15; 55(4):537-45. PubMed ID: 18533199
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
    Bennouar KE, Uberti MA, Melon C, Bacolod MD, Jimenez HN, Cajina M, Kerkerian-Le Goff L, Doller D, Gubellini P.
    Neuropharmacology; 2013 Mar 15; 66():158-69. PubMed ID: 22491024
    [Abstract] [Full Text] [Related]

  • 14. Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats.
    Lopez S, Turle-Lorenzo N, Johnston TH, Brotchie JM, Schann S, Neuville P, Amalric M.
    Neuropharmacology; 2008 Sep 15; 55(4):483-90. PubMed ID: 18625257
    [Abstract] [Full Text] [Related]

  • 15. mGluR7 undergoes rapid internalization in response to activation by the allosteric agonist AMN082.
    Pelkey KA, Yuan X, Lavezzari G, Roche KW, McBain CJ.
    Neuropharmacology; 2007 Jan 15; 52(1):108-17. PubMed ID: 16914173
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Beta-arrestin1 and 2 differently modulate metabotropic glutamate receptor 7 signaling in rat developmental sevoflurane-induced neuronal apoptosis.
    Wang WY, Wu XM, Jia LJ, Zhang HH, Cai F, Mao H, Xu WC, Chen L, Zhang J, Hu SF.
    Neuroscience; 2016 Jan 28; 313():199-212. PubMed ID: 26621121
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological interference with metabotropic glutamate receptor subtype 7 but not subtype 5 differentially affects within- and between-session extinction of Pavlovian conditioned fear.
    Toth I, Dietz M, Peterlik D, Huber SE, Fendt M, Neumann ID, Flor PJ, Slattery DA.
    Neuropharmacology; 2012 Mar 28; 62(4):1619-26. PubMed ID: 22079159
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.